messenger RNA
Enable an agent to recognise messenger RNA, assess its molecular and functional state, and determine suitable handling, analysis and translation-related uses.
Research draft, second pass
A second pass drafted this model: the structure a model of this thing needs, and what is known about it in the world. The line under this one says how the second half was obtained - researched against sources, or recalled without web access, in which case nothing here was read anywhere and every claim is a lead to verify. Unreviewed either way.
recalled by Codex without web access - no source was read
Researched by: Codex
Purpose and description
Enable an agent to recognise messenger RNA, assess its molecular and functional state, and determine suitable handling, analysis and translation-related uses.
Messenger RNA (mRNA) is a class of ribonucleic acid molecules whose nucleotide sequences serve as templates for ribosomal synthesis of proteins.
It can be Identify a transcript and compare it with a reference or engineered specification.; Map coding regions and assess whether processing and architecture suit a specified translation context.; Quantify transcript abundance, intact material and preparation impurities.; Select compatible handling and analytical conditions using preparation-specific evidence.; Evaluate translation competence in a defined assay.; Determine whether evidence supports an intended use or whether further characterisation is required..
Distinguishing features
Establish that the material is RNA rather than DNA using sequence chemistry or suitable analytical evidence.
Identify an evidenced or intended role as a protein-translation template; an apparent open reading frame alone does not establish messenger RNA identity.
Distinguish messenger RNA from transfer RNA and ribosomal RNA by its coding-template role rather than merely its presence near ribosomes.
Distinguish precursor, mature and degraded transcript states without assuming that every messenger RNA requires the same processing steps.
Separate the RNA molecule from a carrier or finished product containing it; carrier properties do not establish transcript identity or integrity.
Scope
+ Transcript identity, sequence variants and natural or engineered origin
+ Protein-coding regions, untranslated regions and translation-relevant architecture
+ Processing, terminal structures and nucleotide modifications
+ Integrity, abundance, purity and translation competence in a specified context
+ Molecular stability, storage conditions and compatibility with intended use
- DNA genes, genomes and transcriptional regulatory systems as independently modelled things
- Transfer RNA, ribosomal RNA and noncoding RNA classes
- Encoded proteins and their downstream biological effects
- Cells, ribosomes and translation machinery as independent systems
- Delivery carriers, formulated medicines and clinical treatment protocols
- Manufacturing processes and laboratory instruments as independent things
Characteristics
- Transcript identity and sequence
- Reference accession and version, organism or construct identifier, sequence and documented differences Names alone cannot distinguish transcript isoforms, engineered variants or sequence revisions.
- Molecular length
- Nucleotides, with treatment of variable tails and incomplete molecules specified Length supports identity and integrity assessment when compared with the expected transcript.
- Coding organisation
- Coding-region coordinates, reading frames, expected products and monocistronic or polycistronic organisation Translation expectations depend on which coding regions the transcript contains.
- Topology and terminal architecture
- Linear or circular; applicable 5' and 3' structures, cap identity and tail identity Architecture affects recognition, translation and degradation and must be interpreted in context.
- Processing state
- Precursor, partially processed, mature for the relevant biological system, or unresolved A transcript can have the expected sequence origin without being ready for its intended function.
- Nucleotide modifications
- Modification identity, location or distribution, occupancy and detection method where known Modification patterns can distinguish preparations and affect their functional behaviour.
- Integrity
- Full-length fraction in percent and fragment-size distribution, with assay and reference RNA quantity alone does not establish the amount of intact coding template.
- Abundance or concentration
- Copies per cell, copies per volume, ng/µL or mol/L, with sampling context and method Biological abundance and preparation concentration answer different operational questions.
- Preparation purity
- Assay-specific amounts or fractions of unwanted RNA species, DNA, proteins and other relevant residuals Impurities can affect interpretation and suitability independently of transcript identity.
- Translation competence
- Untested, demonstrated, reduced or undetected in a named translation system with controls Functional conclusions require a compatible system and cannot follow from sequence alone.
Also called
Where this came from
wikidata · CC0 1.0
Drafted structure
Bundle to layer to finding to question, as the second pass will find it: 5 bundles · 9 layers · 15 findings · 23 questions.
Transcript identity Establish which messenger RNA is being represented and at what level.
Messenger RNA is a heterogeneous molecular class, so a class name cannot substitute for transcript or preparation identity.
Reference and origin
Connect the RNA to its sequence reference and biological or engineered origin.
Sequence grounding
Record the evidence needed to identify the transcript without treating a gene name as an exact RNA sequence.
- Which accession, version or explicit sequence identifies this transcript, and which differences are documented? definition
- Was this RNA observed in a biological source or produced from an engineered template, and what evidence establishes that origin? provenance
Identity boundaries
Separate the molecular class, transcript variant and physical preparation.
Transcript versus preparation
Clarify whether assertions apply to a sequence-defined transcript or to material that may contain multiple RNA species.
- Does the represented thing denote the messenger RNA class, a transcript isoform, an engineered construct or a particular preparation? boundary
- Which sequence, tail-length or modification differences are included within this identity, and which require a separately identified variant? boundary
Coding and maturation Describe the architecture that makes the RNA a candidate translation template.
Coding sequence, processing and terminal structures must be interpreted together and in the relevant biological system.
Coding architecture
Locate coding regions and translation-relevant noncoding portions.
Translation template map
Capture coding-region assignments and their supporting evidence without equating every possible reading frame with an expressed product.
- Which coding regions, initiation sites, termination sites and expected products are supported, and which remain predictions? definition
- Which untranslated regions or other sequence elements must be retained for the intended translation context? action
Processing and chemistry
Characterise maturation, topology, termini and nucleotide modifications.
Contextual maturity
Assess maturity against the requirements of the particular transcript and system rather than a universal checklist.
- Which processing steps are applicable, and what evidence distinguishes precursor, partially processed and mature material? measurement
- What topology, cap or other terminal chemistry, tail distribution and nucleotide modifications are measured or specified? measurement
Molecular and functional state Assess how much relevant RNA is present and whether it performs its template function.
Sequence identity and bulk RNA concentration do not establish intactness, purity or functional translation.
Quantity and integrity
Distinguish total detected RNA from intact target transcript.
Intact target assessment
Relate abundance measurements to transcript specificity, fragmentation and unwanted material.
- How much target RNA is present, in which units, and can the assay distinguish it from fragments and other RNA species? measurement
- What evidence establishes full-length fraction and relevant impurities, including unwanted double-stranded RNA where applicable? measurement
Translation evidence
Link functional claims to a specified translation system and readout.
Context-bound competence
Record whether the transcript produces the expected product under tested conditions and what limits that conclusion.
- In which cellular or cell-free system was translation tested, and how were product identity and output assessed? measurement
- Which controls distinguish a transcript defect from delivery failure, assay limitations or incompatibility with the translation system? measurement
Stability and use Connect preparation history and stability evidence to handling and use decisions.
Messenger RNA suitability depends on its present condition and preparation context, not just its original specification.
Handling and persistence
Track conditions and events that may change integrity or function.
Condition-dependent stability
Record stability evidence for the actual RNA preparation and distinguish it from cellular turnover measurements.
- What temperature, buffer, RNase-control measures and storage duration are supported for this preparation? action
- What handling history, freeze-thaw exposure or measured degradation limits confidence in its current condition? provenance
Intended-use qualification
Determine whether the characterised RNA meets the needs of a particular use.
Use-specific evidence
Tie acceptance decisions to transcript properties while linking formulation and product-level decisions to neighbouring models.
- Which identity, integrity, purity and functional acceptance criteria must this RNA meet for the intended use? action
- Which handling or use constraints arise from the RNA sequence and encoded product, and which belong to the carrier, formulation or finished product? boundary
Evidence and external alignment What the world already says about this thing, gathered so the model can be checked against it.
A model that cannot be lined up against existing standards, identifiers and practice cannot be adopted by anyone who already uses them.
Reported evidence
Findings from the breadth pass, kept separate from the structural claims.
Check these first
Recalled without web access and unsourced; every item is a lead to verify.
- This is recall without source consultation; length and half-life ranges are broad biological generalizations.
- mRNA is a sequence-diverse molecular class, so a single molecular formula, molecular mass, purity specification or hazard classification would be misleading.
- A 5' cap, poly(A) tail and removal of introns are common features of mature nuclear-encoded eukaryotic mRNA, not universal requirements for all mRNA.
- Which of these check these first hold for the sense of messenger RNA this model covers, and on what evidence? provenance
Kinds and varieties
Recalled without web access and unsourced; every item is a lead to verify.
- Monocistronic mRNA, containing one principal protein-coding region
- Polycistronic mRNA, containing multiple protein-coding regions
- Nuclear-encoded eukaryotic mRNA
- Organelle-encoded mRNA
- Viral mRNA
- Synthetic mRNA produced by in vitro transcription
- Which of these kinds and varieties hold for the sense of messenger RNA this model covers, and on what evidence? provenance
Identifiers and schemes
Recalled without web access and unsourced; every item is a lead to verify.
- NCBI RefSeq - NM_<digits>.<version> or XM_<digits>.<version> - Identifies individual protein-coding transcript reference sequences; NM_ denotes curated records and XM_ denotes computational model records. These are not identifiers for mRNA as a material class.
- INSDC sequence accession - Accession followed by a numeric sequence version - GenBank, ENA and DDBJ share this system for nucleotide sequence records, including deposited mRNA sequences.
- Which of these identifiers and schemes hold for the sense of messenger RNA this model covers, and on what evidence? provenance
Real-world use
Recalled without web access and unsourced; every item is a lead to verify.
- Carries coding information to ribosomes during cellular protein synthesis.
- Transcript abundance and sequence are measured to investigate gene expression.
- Synthetic mRNA directs production of antigens in mRNA vaccines.
- Introduced mRNA enables transient protein expression in research and biotechnology.
- Detection of particular transcripts supports molecular diagnostic assays.
- Which of these real-world use hold for the sense of messenger RNA this model covers, and on what evidence? provenance
Typical measurements
Recalled without web access and unsourced; every item is a lead to verify.
- Transcript length - Commonly hundreds to several thousand nucleotides; some transcripts are much longer - nucleotide
- Intracellular half-life - Often minutes in bacteria and minutes to many hours in eukaryotes; strongly dependent on transcript and conditions - minute or hour
- Which of these typical measurements hold for the sense of messenger RNA this model covers, and on what evidence? provenance
Failure modes and hazards
Recalled without web access and unsourced; every item is a lead to verify.
- RNase contamination and chemical hydrolysis fragment mRNA and reduce its usefulness as a translation template.
- Sequence errors, incorrect processing or unsuitable untranslated regions can alter the protein produced or impair expression.
- Unprotected extracellular mRNA is vulnerable to degradation and generally enters cells inefficiently.
- Introduced RNA can activate innate immune responses; effects depend on sequence, chemical modifications, impurities and delivery.
- Double-stranded RNA by-products in synthetic preparations can contribute to unwanted immune activation; toxicity can also arise from the encoded protein or delivery formulation.
- Which of these failure modes and hazards hold for the sense of messenger RNA this model covers, and on what evidence? provenance
Neighbouring kinds and how to tell them apart
Recalled without web access and unsourced; every item is a lead to verify.
- RNA - RNA is the broader molecular class; mRNA is distinguished by its role as a protein-coding translation template.
- Pre-mRNA - Pre-mRNA is a precursor requiring processing to form mature mRNA, commonly including splicing in eukaryotes.
- Transfer RNA - Transfer RNA delivers amino acids and decodes mRNA codons rather than supplying the protein-coding template.
- Ribosomal RNA - Ribosomal RNA forms structural and catalytic components of ribosomes rather than serving as their protein-coding template.
- Complementary DNA - Complementary DNA is DNA copied from an RNA template; its sugar chemistry and molecular role differ from those of mRNA.
- mRNA vaccine - An mRNA vaccine is a formulated medicinal product containing antigen-encoding mRNA; mRNA itself is a much broader molecular class.
- Which of these neighbouring kinds and how to tell them apart hold for the sense of messenger RNA this model covers, and on what evidence? provenance
What the second pass must settle
- Should this registry entry include precursor messenger RNA directly, or represent it through a related precursor model and maturation relation?
- How should circular translation templates and engineered self-amplifying RNA constructs relate to this entry without conflating distinct molecular categories?
- What evidence threshold distinguishes a messenger RNA from an RNA with a predicted but unverified coding region?
- Which assay-specific integrity and translation criteria can be shared across transcript types, and which must remain preparation-specific?
- Which identifiers and handling classifications meaningfully apply to the broad messenger RNA class versus an exact sequence, preparation or formulated product?